Vaccine Adjuvants Market Size Forecast to Reach $1.67 Billion by 2025

Vaccine Adjuvants Market size is forecast to reach $1.67 billion by 2025, growing at a CAGR of 8.24% during the forecast period 2020-2025. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. Aluminum adjuvants are used in vaccines such as hepatitis A, hepatitis B, diphtheria and tetanus-containing vaccines. Protection via donated antibodies is short-lived, whereas protection via the tetanus shot lasts 10 years or more. Immunologic adjuvants are often used to modify or augment the effects of a vaccine by stimulating the immune system to respond to the vaccine more vigorously, and thus providing increased immunity to a particular disease. Immunostimulants and adjuvants can be administered before, with, or after vaccines to amplify the specific immune response generating elevations of circulating antibody titers and numbers of plaque-forming cells. Rapidly increasing incidences of various diseases among the masses, increasing demand for improved vaccine treatments, increasing R&D activities and investments, and government investments for providing vaccine dosage to the people are driving the market growth in recent years. In addition, urgent need for vaccine development of novel coronavirus (COVID-19) and major product launches of key players like Seppic and Seqirus are other factors driving the growth of the market.

Key Takeaways

North America dominated the Vaccine Adjuvants Market in the year 2019 owing to increasing demand for improved medical results from vaccines, widespread transmission of coronavirus, growing prevalence of infectious diseases and increasing government investments for improvements in healthcare sector. The Vaccine Adjuvants Market scope for different regions will be provided in the final report.
Growing prevalence of infectious and chronic diseases in the last decade, increasing investments in R&D activities of vaccine, demand for vaccine of novel coronavirus (COVID-19) and increasing government expenditure for vaccine awareness programs have helped in significant growth of Vaccine Adjuvants Market.
Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Vaccine Adjuvants Market report.
Higher costs of adjuvant vaccine products are anticipated to hamper the market growth of the Vaccine Adjuvants Industry.

Product Type – Segment Analysis

Particulate Adjuvants held the largest share in the product type segment of Vaccine Adjuvants Market in 2019 and is estimated to grow at a CAGR of 7.5% during the forecast period 2020-2025. Particulate adjuvants have witnessed a surge in their market share, owing to their efficient treatments and several advantages. These include passive targeting to the antigen-presenting cells within the immune system, protection against adjuvant degradation, and ability for sustained antigen release. Aluminum salts are by far the most commonly used adjuvants in vaccines. There are only two aluminium salts which are used in clinically-approved vaccines, Alhydrogel and AdjuPhos, while the novel aluminium adjuvant used in Gardasil is a sulphated version of the latter. Increasing popularity of aluminium adjuvants is attributed to their quicker clinical approvals, better potential clinical services in its history and enhanced delivery of antigen to immune system. These factors have aided the market growth in the past few years on a large scale. Combination Adjuvants held the second largest share in 2019. With the help of combined strategies, the vaccine becomes capable of provoking an abundant and effective immunization to compete against antigens with minimal/no adverse effects on recipients. Pathogen Components is set to be the fastest growing segment and is estimated to register the highest CAGR during the forecast period 2020-2025, owing to increasing R&D activities and newer product developments by market companies.

Disease Type – Segment Analysis

Infectious Diseases hold the major share in the disease type segment of Vaccine Adjuvants Market in 2019. This growth is primarily driven by the large number of incidences every year. According to the World Health Organization (WHO), nearly 50,000 men, women and children are dying every day from infectious diseases. Diseases like malaria, dengue, influenza and hepatitis A, B & C are taking lives every year on a high rate. Secondary factors helping the growth include growing mass awareness about treatment by vaccines and presence of advanced pipeline products for vaccine adjuvants for treatment of infectious diseases. Cancer is forecast to grow at the fastest rate with the highest CAGR during the forecast period 2020-2025, owing to increasing cancer treatments across the world and major R&D activities by market players on cancer targeted drugs and therapies.

Geography – Segment Analysis

North America dominates the geography segment of Vaccine Adjuvants Market with a share of more than 41.55% in 2019, followed by Europe. Rising incidence of serious epidemic diseases, demand for vaccine of novel COVID-19 amidst the widespread fatalities, high healthcare expenditure by the government and presence of key market players in this region have helped in the growth of Vaccine Adjuvants Market infrastructure. Europe held the second place in the geography segment share of the market, owing to presence of a well-developed healthcare infrastructure, growing prevalence of epidemics and presence of key market players in this region.

However, Asia-Pacific is estimated to grow at the fastest rate at a higher CAGR during the forecast period 2020-2025. This is owing to growing technological innovations in the healthcare sector, increasing awareness about vaccines, and increasing disposable income of the population.

Drivers – Vaccine Adjuvants Market

Growing prevalence of infectious and chronic diseases

Infectious diseases are a leading cause of death worldwide, particularly in low income countries, especially in young children. Three infectious diseases were ranked in the top ten causes of death worldwide in 2016 by the World Health Organization. They are lower respiratory infections (3.0 million deaths), diarrheal diseases (1.4 million deaths), and tuberculosis (1.3 million deaths). Another infectious disease, malaria, accounts for a top cause of death in low income countries. On the other hand, chronic diseases has been rapidly increasing worldwide. It is estimated that by 2025, chronic diseases is set to contribute approximately to 60% of the 56.5 million total reported deaths in the world and approximately 46% of the global burden of disease. This has resulted in widespread demand for vaccines for proper treatment in less time. In recent months, there is a huge demand of Vaccine Adjuvants for COVID-19, which has further aided the market growth.

Increasing government expenditure for vaccine awareness programs
Ministries of Health in many countries are continually confronted with the challenge of protecting resources for essential programs from the vagaries of the domestic budgeting process and the volatility in external donor financing. Adequate and reliable health financing is one of several essential elements required to ensure continuity in service delivery, and to fund continuous increases in coverage, quality and access to health services. This is all the more important for disease specific preventive programs such as immunization. The health benefits of vaccination has helped people and government become aware and invest in development of vaccine products. This has fuelled the market growth by a large scale. R&D activities for finding vaccines for proper treatment of COVID-19 is projected to further drive the Infusion Market growth during the forecast period 2020-2025.

Challenges – Vaccine Adjuvants Market

Higher costs of adjuvant vaccine products and development

Adjuvanted vaccines would be cost-effective at a $1 adjuvant cost (on top of the standard vaccine cost) when the adjuvant efficacy (in overcoming the difference between vaccine response in patients and healthy adults) is greater than or equal to 60% and economically dominant (provides both cost savings and health benefits) when the $1 adjuvant’s efficacy is 100%. In most cases, this is out of the reach of the average patient. This is anticipated to hamper the market growth during the forecast period 2020-2025.

Vaccine Adjuvants Industry Outlook

Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the Vaccine Adjuvants Market. In 2019, Vaccine Adjuvants Market share is consolidated by the top players present in the market. Vaccine Adjuvants Market top 10 companies are Brenntag Biosector A/S, Seppic, Seqirus, Agenus, Inc., Novavax, Inc., Invivogen, SPI Pharma, Inc., Avanti Polar Lipids, Inc., MVP Laboratories, Inc. and OZ Biosciences among others.

Acquisitions/Product Launches

In April 2020, Seppic announced the launch of its new product, Montanide™ ISA 78 VG. Montanide™ ISA 78 VG is an innovative alternative to Montanide™ ISA 71 VG and Montanide™ ISA 71R VG. Designed for water-in-oil emulsions, this novel adjuvant is particularly stable and powerful.
In February 2020, Seqirus announced the U.S. FDA approval of its first-ever adjuvanted, cell-based pandemic influenza A (H5N1) Vaccine.
In April 2019, Agenus announced that the first patient was dosed in the clinical trial of its next-generation anti-CTLA-4 antibody (AGEN1181). AGEN1181, a novel ‘Fc engineered’ antibody with potential for enhanced anti-tumor functions, is specifically designed to boost cancer killing immune cells and deplete cells that block the activity of these cancer killing cells.